

**SM MOGHIMI; BSc (Man.), PhD (Lond.), FIoN**

Department of Pharmaceutics and Analytical Chemistry

University of Copenhagen

Universitetsparken 2

DK-2100 Copenhagen Ø

Denmark

☎: +45 35 33 65 28; Fax: +45 35 33 60 30

E-mail: [momo@farma.ku.dk](mailto:momo@farma.ku.dk)

<http://www.farma.ku.dk/index.php/Nanomedicine/8313/0/>



Moein Moghimi is Professor of Nanomedicine and Head of the Nanomedicine Group at the Department of Pharmaceutics and Analytical Chemistry (Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark). He further serves as the Director of the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) and Group Leader in Pharmaceutical Nanotechnology at the NanoScience Center (University of Copenhagen). He is also the Guest Professor of Nanomedicine at Multidisciplinary Research Center, Shantou University (China) and the elected Fellow of the Institute of Nanotechnology (FioN) in UK. Previously he was Senior Lecturer in Biopharmacy and Molecular Pharmaceutics at the School of Pharmacy, University of Brighton (UK), and The University Research Fellow in Advanced Drug Delivery Systems at the Department of Pharmaceutical Sciences, University of Nottingham (UK). His research activities are focused on experimental nanomedicines, nanotoxicology and pharmaceutical nanotechnology. He has pioneered research in design and surface engineering of nanoparticles and functional nanosystems for parenteral site-specific targeting and imaging modalities (e.g., splenotropic entities, lymphotropic agents, ‘phagocyte-resistant’ nanoparticles and cancer nanomedicines) as well as the molecular basis of nanomaterial cytotoxicity (single cell studies) and adverse immunological reactions (complement activation mechanisms). Professor Moghimi has been the recipient of numerous awards and most recently was honoured with the Faculty of Pharmaceutical Sciences Research Achievement Award (Copenhagen University). His contributions to peer-reviewed high impact international journals include over 90 original full research papers and invited critical reviews and more than 40 book chapters, business reports, editorials, and patents. Since 2009, Professor Moghimi has secured over 7 million Euros in competitive research funds in nanomedicine and bionanotechnology and act as principal investigator of numerous nanomedicine research projects and partnering European Commission FP-7 programmes.

Professor Moghimi has previously served as invited Theme Editor for a number of *Theme Issues* of the prestigious *Advanced Drug Delivery Reviews* (Elsevier, The Netherlands) and currently act as the European Editor of *NanoMed Journal* (Pan Stanford, Singapore). Associate Editor for both *Nanomedicine: Nanotechnology, Biology and Medicine* (Elsevier) and *Journal of Biomedical Nanotechnology* (American Scientific Publishers, USA) as well as being a member of editorial/advisory board of 12 other international journals to include *Advanced Drug Delivery Reviews*, *Nanomedicine-UK (Future Medicine)*, *Journal of Liposome Research (Informa Healthcare)*, *Drug Delivery (Informa Healthcare)*, *Recent Patents in Drug Delivery and Formulation (Bentham)* and *Current Drug Discovery Technologies (Bentham)*. He further practices in the capacity of consultant to numerous pharmaceutical, biotechnology, health, and food industries as well as investment banks, management consultancy firms and other entrepreneurial enterprises world-wide and was an invited evaluator for Nanotechnology/Nanomedicine Centres of Excellence in Germany and Austria. Other responsibilities include being a regular invited assessor and expert in drug delivery systems and nanomedicine for various research councils and organizations world-wide. To date, Professor Moghimi has been an appointed reviewer to over 1000 manuscripts for more than 100 international journals and has delivered over 250 invited presentations and keynote lectures in more than 25 countries as well as being regular conference chair and organizer.

In 1985, he graduated with Honors in Biochemistry from The University of Manchester (UK) and in 1989 completed a PhD in Biochemistry (liposome immunobiology) at the Charing Cross Hospital Medical School (Imperial College, University of London, UK).

*Representative recent publications:*

1. **Moghimi, S. M., Andersen, A. J., Ahmadvand, D., Wibroe, P., Andresen, T. L. and Hunter, A. C.** (2011) Material properties in complement activation. *Adv. Drug. Deliv. Rev.* (in press).
2. **Moghimi, S. M., Hunter, A. C. and Andresen, T. L.** (2012) Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. *Ann. Rev. Pharmacol. Toxicol.* (in press).
3. **Moghimi, S. M., Peer, D. and Langer R.** (2011) Re-shaping the future of nanopharmaceuticals: qua vadis? *Nature Biotechnol.* (under review).
4. **Ahmadvand, D., Rahbarizadeh, F. And Moghimi, S.M.** (2011) Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). *Curr. Opin. Biotechnol.* (in press).
5. **Sadeqzadeh, E., Rahbarizadeh, F., Ahmadvand, D., Rasaee, M. J., Parhamifar, L. and Moghimi, S. M.** (2011) Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. *J. Control. Rel.* (in press).
6. **Hamad, I., Al-Hanbali, O., Hunter, A. C., Rutt, K. J., Andresen, T. L. and Moghimi, S. M.** (2010) Distinct polymer architecture mediates complement activation pathways at nanosphere-serum interface: implications for stealth nanoparticle engineering. *ACS Nano* **4**: 6629–6638. Featured as **News and Views** in *Nature Nanotechnol.* 2011: **6**, 80–81.
7. **Moghimi, S. M. and Hunter, A. C.** (2010) Complement monitoring of carbon nanotubes. *Nature Nanotechnology* **5**: 382–382.
8. **Moghimi, S. M., Andersen, A. J., Hashemi, S. H., Lettiero, B., Ahmadvand, D., Hunter, A. C., Andresen, T. L., Hamad, I. and Szebeni, J.** (2010) Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. *J. Control. Rel.* **146**: 175–181.
9. **Parhamifar, L., Larsen, A. K., Hunter, A. C., Andresen, T. and Moghimi, S. M.** (2010) Polycation cytotoxicity: a delicate matter for nucleic acid therapy. Focus on polyethylenimine. *Soft Mat.* **6**: 4001–4009.

10. **Moghimi, S. M. and Andresen, T. L.** (2009) Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicine. *Mol. Immunol.* **46**: 1571–1572.
11. **Hamad, I., Hunter, A. C., Szebeni, J. and Moghimi, S. M.** (2008) Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. *Mol. Immunol.* **46**: 225–232.
12. **Hamad, I., Hunter, A. C., Rutt, K. J., Liu, Z., Dai, H. and Moghimi, S. M.** (2008) Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. *Mol. Immunol.* **45**: 3797–3803.
13. **Moghimi, S. M. and Moghimi, M.** (2008) Enhanced lymph node retention of subcutaneously injected IgG-PEG-liposomes through pentameric IgM antibody-mediated vesicular aggregation. *Biochim. Biophys. Acta-Biomembranes* **1778**: 51–55.
14. **Mukhopadhyay, R., Al-Hanbali, O., Pillai, S., Hemmersam, A. G., Meyer, R. L., Hunter, A. C., Rutt, K. J., Besenbacher, F., Moghimi, S. M. and Kingshott, P.** (2007) Ordering of binary polymeric nanoparticles on hydrophobic surfaces assembled from low volume fraction dispersions. *J. Am. Chem. Soc.* **129**: 13390–13391.
15. **Moghimi, S. M.** (2006) The effect of methoxyPEG chain length and molecular architecture on lymph node targeting of immuno-PEG-liposomes. *Biomaterials* **27**: 136–144.
16. **Moghimi, S. M., Hamad, I., Andresen, T. L., Jørgensen, K. and Szebeni, J.** (2006) Methylation of the phosphate oxygen moiety of phospholipid-methoxypoly(ethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. *FASEB J.* **20**: 2591–2593 (doi: 10.1096/fj.06-6186fje, electronic pages E2057–E2067).
17. **Moghimi, S. M., Hunter, A. C. and Murray, J. C.** (2005) Nanomedicine: current status and future prospects. *FASEB J.* **19**: 311–330.
18. **Moghimi, S. M., Symonds, P., Murray, J. C., Hunter, A. C., Debska, G. and Szewczyk, A.** (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene-transfer/therapy. *Mol. Ther. (Am. Soc. Gene Ther.)* **11**: 990–995.
19. **Symonds, P., Murray, J. C., Hunter, A. C., Debska, G., Szewczyk, A. and Moghimi, S. M.** (2005) Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. *FEBS Lett.* **579**: 6191–6198.
20. **Moghimi, S. M., Hunter, A. C., Murray, J. C. and Szewczyk, A.** (2004) Cellular distribution of nonionic micelles. *Science* **303**: 626–627.

*Professor Moghimi is listed in Marquis Who's Who in the World, USA, Marquis Who's Who in Science and Engineering, USA, and Marquis Who's Who in Medicine and Healthcare, USA (by invitation).*